Contact Information:

Media Contact

Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313

Twitter: PennMedNews

http://www.uphs.upenn.edu/news/




Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.

PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION
RSS - Press News Release
Add Press Release

Penn team: Sustained remission of multiple myeloma after personalized cellular therapy

New treatment combination with CTL019 targets precursors of cancerous white blood cells


2015-09-10
(Press-News.org) PHILADELPHIA - A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania. The investigational treatment was combined with chemotherapy and an autologous stem cell transplant - a new strategy designed to target and kill the cells that give rise to myeloma cells.

The team's findings are published in a case report today in the New England Journal of Medicine. Prior to receiving the therapy, the patient had already received nine different therapy regimens in the five years since her diagnosis, including a previous autologous stem cell transplant, which had only controlled her disease for a few months. Her bone marrow was almost entirely filled by cancerous cells when she entered the study. By 130 days after receiving the infusion of engineered cells, tests revealed no evidence of disease. The patient - who was the first to be treated as part of this trial - remains in remission more than 12 months after receiving this therapy.

The new report expands on data that were presented during the American Society of Clinical Oncology meeting in June 2015 about the first five myeloma patients to receive CTL019, which was tested in trials for leukemia beginning in 2010. Now, the Penn researcher team also report updates on the myeloma trial's overall progress: Of ten patients who have received the therapy to date, six remain progression-free, though two patients have only very recently been treated.

"We couldn't be more pleased with this patient's response," said the study's co-lead author, Alfred Garfall, MD, an assistant professor of Hematology/Oncology in Penn's Abramson Cancer Center and Perelman School of Medicine. "We believe her CTL019 cells made the difference, since we would not have expected such a durable remission with a transplant alone, considering the very transient response this patient had to her first transplant several years ago."

CTL019 begins with each patient's own T cells, collected through a procedure similar to dialysis. The cells are then reprogramed to hunt and potentially kill cancer cells in the patient's body. Patients who have enrolled in trials of this approach for acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) typically undergo lymphodepleting chemotherapy before receiving an infusion of their newly engineered cells. The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later. Although myeloma is, like leukemias and lymphomas, a cancer involving white blood cells known as lymphocytes, myeloma cells don't traditionally express CD19 on their surface because they arise from the most mature type of lymphocytes - plasma cells.

"There was some skepticism about whether a CD19-directed therapy would work in this disease, since nearly all of these patients' cancerous plasma cells do not express CD19," said the study's senior author, Edward Stadtmauer, MD, chief of Hematologic Malignancies and a professor of Hematology/Oncology in Penn's Abramson Cancer Center and Perelman School of Medicine. "Since there was data showing that the possible stem cells can be CD19-positive, our hypothesis was that we may be able to devise a therapy targeted at early precursors of those cells."

The patient experienced transplantation-related side effects during the time prior to receiving CTL019, including neutropenia and thrombocytopenia, nausea, fever, and an infection. After receiving the engineered cells, she experienced no fevers or other signs of cytokine release syndrome (CRS), a condition that has been observed in other patients undergoing CTL019.

Funding for the study was supported in part by Novartis, by grants from the National Institutes of Health (K12CA076931, K08CA166039, and 5R01CA165206) and the Conquer Cancer Foundation.

Editor's notes: The University of Pennsylvania has licensed technologies involved in this trial to Novartis. Some of the scientists involved in these trials are inventors of these technologies. As a result of the licensing relationship with Novartis, the University of Pennsylvania receives significant financial benefit, and these inventers have benefitted financially and/or may benefit financially in the future. Additional disclosure information is available in the paper.

Because CTL019 is an investigational therapy, the safety and efficacy profile has not yet been established. Access to investigational therapies is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the therapy. After CTL019 infusion, cytokine release syndrome (CRS) may occur when the engineered cells become activated and multiply in the patient's body resulting in the release of cytokines. During CRS, patients typically experience varying degrees of flu-like symptoms with high fevers, nausea, muscle pain, and in some cases, low blood pressure and breathing difficulties. CRS severity correlates with disease burden. Additionally, CRS also can occur in other non-CAR therapy settings including some monoclonal antibodies.

INFORMATION:

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.9 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $409 million awarded in the 2014 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2014, Penn Medicine provided $771 million to benefit our community. CONTACT: Holly Auer
O: 215-349-5659
C: 215-200-2313
holly.auer@uphs.upenn.edu


ELSE PRESS RELEASES FROM THIS DATE:

New enzyme-replacement therapy shows promise for genetic lipid disease treatment

2015-09-10
PHILADELPHIA--Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies. Lysosomal acid lipase deficiency (LALD) is an LSD that causes fatty liver disease and cirrhosis. There is no treatment for the disease, which afflicts 1- 40,000 - 1 in 300,000 people across the world. In this week's New England Journal of Medicine, researchers report results of a trial showing the efficacy of a new enzyme-replacement therapy for LALD. In an accompanying editorial, Daniel J. Rader, ...

Study defines clinical trials likely to exclude patients with brain metastases

2015-09-09
Non-small cell lung cancer frequently spreads to the central nervous system (CNS), but patients with CNS metastases may be excluded from clinical trials of new drugs. A University of Colorado Cancer Center study being presented at the 16th World Conference on Lung Cancer reveals the full extent to which the CNS may be under-explored in clinical research. The study combed the website ClinicalTrials.gov to identify 413 open lung cancer clinical trials. Overall, 41 percent of trials only included patients if their CNS disease was previously treated. Twenty-six percent allowed ...

A new marker for migraine?

2015-09-09
MINNEAPOLIS - Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the September 9, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology. Episodic migraine is defined as having less than 15 headaches per month. "While more research is needed to confirm these initial findings, the possibility of discovering a new biomarker for migraine is exciting," said study author B. Lee Peterlin, DO, with the Johns Hopkins University School of Medicine in Baltimore and a member ...

Patients prefer relief from lower back pain over improved mobility

2015-09-09
A new study out today in the journal Neurology examines the question of quality of life for individuals with a common form of lower back pain called lumbar spinal stenosis. The findings show that, when asked to choose between treatments that reduced pain or would help them stand or walk, patients overwhelmingly chose pain relief. "There has long been a debate in the medical community over striking the right balance between pain relief and physical function," said John Markman, M.D., director of the Translational Pain Research Program in the University of Rochester ...

Last chance for oasis in China's desert

Last chance for oasis in Chinas desert
2015-09-09
This news release is available in German. Ten percent of the world's cotton is produced in the Xinjiang region in northwestern China. Irrigating the cotton fields, however, is causing ecological problems. After many years of research, a team of international researchers headed by Prof. Markus Disse at the Technical University of Munich (TUM) has developed a set of recommendations aimed at preserving the local environment. The Tarim basin in the Xinjiang region of northwestern China is unique. No other natural landscape is located as far from the ocean. It has ...

Discrimination during adolescence has lasting effect on body

2015-09-09
EVANSTON, Ill. --- In both blacks and whites, everyday feelings of discrimination can mess with the body's levels of the primary stress hormone, cortisol, new research suggests. In African-Americans, however, the negative effects of perceived discrimination on cortisol are stronger than in whites, according to the study, one of the first to look at the biological response to the cumulative impact of prejudicial treatment. The team of researchers, led by Northwestern University, also found that the teenage years are a particularly sensitive period to be experiencing ...

Can black Republicans win black votes? Not likely, UC study finds

2015-09-09
Are black voters more likely to vote for black candidates, regardless of political party affiliation? A new study by a University of Cincinnati researcher presents discouraging news for Republican leaders hoping to win over this Democratic stronghold by nominating black Republican candidates for political offices. "There are some very successful African-American Republicans, but those folks don't attract African-American votes," said the study's author, David Niven, a University of Cincinnati professor of political science. "Party matters so much more than race." In ...

Michigan 'See You in 7' program helps reduce heart failure readmissions

2015-09-09
Michigan hospitals participating in the American College of Cardiology's "See You in 7" program demonstrated important reductions in 30-day readmission rates for Medicare heart failure patients when compared to non-participating hospitals despite only modest increases in seven-day follow-up appointments, according to a study today in JACC: Heart Failure. "See You in 7" is part of the ACC's Hospital-to-Home initiative, a national quality improvement program aimed at reducing heart disease-related hospital readmissions and improving the transition from hospital to home. ...

Bats may use bidirectional echolocation to detect prey, orient themselves

Bats may use bidirectional echolocation to detect prey, orient themselves
2015-09-09
The barbastelle bat may emit two different types of weak echolocation signals alternately, one upward through the nose and one downward through the mouth, to find prey while undetected and to sufficiently keep track of the environment, respectively, according to a study published September 9, 2015 in the open-access journal PLOS ONE by Anna-Maria Seibert and colleagues from the University of Tübingen, Germany. Barbastelle bats prey almost exclusively on eared moths, using "stealth echolocation" signals that are 10-100 times weaker than those of other aerial hawking ...

UQ scientists close in on first dengue treatment

UQ scientists close in on first dengue treatment
2015-09-09
Clinical trials for a dengue fever treatment could start within a year, following a discovery by University of Queensland scientists. UQ's School of Chemistry and Molecular Biosciences Head Professor Paul Young said the researchers had identified similarities in how the body reacted to dengue virus and bacterial infections, in a finding that would allow them to re-purpose existing drugs. "We have discovered that the dengue virus NS1 protein acts as a toxin in the body, in a similar manner to the way bacterial cell wall products lead to septic shock in bacterial infections," ...

LAST 30 PRESS RELEASES:

How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[Press-News.org] Penn team: Sustained remission of multiple myeloma after personalized cellular therapy
New treatment combination with CTL019 targets precursors of cancerous white blood cells
Press-News.org is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.